Fifteenth of the "ASCO Direct™ China" webinar:Next Generation Immuno-oncology: Beyond PD-1/L1

About this Event

Webinar Date:

  • China Time: Saturday, November 7th, 9:00 AM
  • US EST Time: Friday, November 6th, 8:00 PM
  • US PST Time: Friday, November 6th, 5:00 PM

Conference Language: English

Venue: Live Zoom Webinar

Webinar Agenda


  • Dr. Jin Li, Shanghai East Hospital
  • Dr. George Fisher, Stanford University


Immune-Related Adverse Events

  • Dr. Hongming Pan, Sir Run Run Shaw Hospital

A Bright Horizon: Novel IO Agents in MDS and AML Patients

  • Dr. David Sallman, Moffitt Cancer Center

Bispecific immunotherapy: Checkpoints, T cell redirection and novel tumor micro-environment activators

  • Dr. Jason Luke, University of Pittsburgh Medical Center and Hillman Cancer Center

Cancer Vaccine Strategies

  • Dr. Nora Disis, University of Washington

Panel Discussion


  • Dr. Jin Li, Shanghai East Hospital
  • Dr. George Fisher, Stanford University

Panelists (alphabetize by last name)

  • Dr. Gong Chen, Sun Yat-sen University Cancer Center
  • Dr. Nora Disis, University of Washington
  • Dr. Jason Luke, University of Pittsburgh Medical Center and Hillman Cancer Center
  • Dr. Hongming Pan, Sir Run Run Shaw Hospital
  • Dr. David Sallman, Moffitt Cancer Center
  • Dr. Junli Xue, Shanghai East Hospital
  • Dr. Xiaotian Zhang, Beijing University Cancer Hospital

Speakers and Panelists Bio


Dr. Jin Li, Shanghai East Hospital

  • 2016-Present: Professor of the Department of Oncology, Tongji University East Hospital, Shanghai, China
  • 2003-2014: Professor and Director of the Department of Medical Oncology, Fudan University Cancer Hospital; Head, Clinical Study Unit of Fudan Cancer Hospital
  • 2000-2002: Post-Doc and visiting scientist in Yale Medical School, USA
  • 1997-1999: Associate professor in the Department of Oncology, ShanghaiChanghai Hospital
  • 1989-1993: Attending and Lecturer in the Department of Obstetrics and Gynecology, Shanghai Changhai Hospital.
  • 1982-1986: Resident in Xichang Railway Hospital in Sichuan Province.


Dr. George Fisher, Stanford University

Dr. George Fisher is a Professor of Medical Oncology at Stanford University where he specializes in gastrointestinal cancers. He received his PhD in Cancer Biology and did all of his medical training at Stanford. Dr. Fisher is co-chair of the GI Committee for ECOG-ACRIN and serves on the NCI GI Steering Committee which is responsible for approving all randomized GI cancer trials within the National Cancer Trials Network (NCTN). His primary interest is in the design and conduct of therapeutic trials but he also collaborates with colleague in molecular biomarker and imaging research.


Dr. Hongming Pan, Sir Run Run Shaw Hospital

Aug/2013-present, Vice Director of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Oct/2012-Apr/2015, Vice Director of Hangzhou Xiasha Hospital, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Jan/2008-Feb/2008, Senior Visiting Scholar, Mayo Clinic Cancer Center, USA

Mar/2000-present, Director of Department of Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Sep/1997-Dec/1997, Visiting Scholar, Loma Linda University Cancer Center, USA

Mar/1996-Feb/2000, Vice Director of Department of Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Aug/1995-Feb/1996, Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang Medical University

Aug/1987-Aug/1990, Resident Doctor, Department of Surgery, Pan'an County People's Hospital

Sep/1990-Jul/1995, Doctor of medicine, Zhejiang Medical University

Sep/1981-Jul/1987, Bachelor of medicine, Zhejiang Medical University


Dr. David Sallman, Moffitt Cancer Center

David Sallman, MD, is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. He is board certified in medical oncology, hematology, and internal medicine. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies (phase 1 and 2 clinical trials) for patients with MDS and AML, based on the underlying mutational drivers of each disease. Dr Sallman has authored or co-authored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. In 2017, he received the Young Investigator Grant from the MDS Foundation, and in 2016, he won the Best Abstract Award at the Moffitt Research Symposium. Dr. Sallman earned his medical degree from the University of South Florida College of Medicine. He completed an internal medicine residency at Massachusetts General Hospital before completing a hematology/oncology fellowship at Moffitt Cancer Center.

My research interests focus on the development of novel, targeted therapeutic strategies for patients with myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) based on the underlying mutational drivers of the disease. Specifically, I study the genetic drivers of myeloid diseases in order to improve prognostication for patients and also to allow for more personalized treatment. I have published significantly on this topic including recently in highly regarded journals including Leukemia and Haematologica and these work are the foundation of clinical trials/translational studies designed to improve the quality of life and survival of patients with MDS. I am also the principal investigator on multiple on-going studies focused on higher risk MDS. Furthermore, my recent work has focused on TP53 mutant MDS where we identified and validated that the clonal burden of TP53 mutation is strongly concordant with patient outcomes and are intimately tied with the clinical trajectory of these patients. Additionally, we have identified that serial next-generation sequencing has significant prognostic value and can be an early biomarker of outcome with novel agents. I have been the lead PI of a phase 1b/2 clinical trial of APR-246 in combination with azacitidine for the treatment of TP53 mutant MDS and AML patients, a proposal which was developed at ASH CRTI. This trial has been one of the highest impact studies in high risk MDS and the data from this trial support the registrational, randomized phase 3 trial that ideally will lead to the first molecularly targeted approval for MDS. This work has led to funding support from Moffitt Cancer Center, Edwards Foundation of the MDS clinical research consortium and an Early Career Award of the Dresner Foundation to support my career goals as an innovative clinical/translational investigator in MDS.


Dr. Jason Luke, University of Pittsburgh Medical Center and Hillman Cancer Center

Jason J. Luke, M.D., F.A.C.P. is an Associate Professor of Medicine at the University of Pittsburgh Medical Center and Hillman Cancer Center where he is the Director of the Cancer Immunotherapeutics Center. Dr. Luke specializes in early phase drug development for solid tumors (particularly novel immunotherapeutics and biomarkers of immunotherapy activity) as well as the management of cutaneous oncology, particularly patients with melanoma. Dr. Luke has been a lead national investigator on clinical trials of immunotherapies including but not limited to anti-PD1/L1, CTLA4, many secondary checkpoints, bispecific approaches (checkpoint, CD3 and cytokine), metabolism modifiers (IDO, A2Ar/CD73/CD39 and arginase), innate agonists of STING, TLRs and oncolytic virus as well as solid tumor cellular therapies (TCRs and CART). Dr. Luke has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy. Dr. Luke’s major translational research focus leverages large scale informatics to advance cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City. Following fellowship, Dr. Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as Staff Physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Thereafter Dr. Luke was an Assistant Professor at the University of Chicago. Dr. Luke is actively involved in several professional societies including the Society for Melanoma Research, the Society for Immunotherapy of Cancer, American Association for Cancer Research and the American Society for Clinical Oncology (ASCO). Dr. Luke has served as the chair of the education committee and as a member of the scientific committee for the melanoma track of the ASCO annual meeting. Dr. Luke has received several awards for research and clinical care including the Melanoma Research Foundation Humanitarian Award, Crain’s 40 under 40, Department of Defense Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from the Melanoma Research Alliance, the Cancer Research Foundation and the Conquer Cancer Foundation of ASCO. Dr. Luke’s research has been supported by ASCO, the National Comprehensive Cancer Network and the National Cancer Institute.


Dr. Nora Disis, University of Washington

Dr. Disis is the Helen B. Slonaker Endowed Professor for Cancer Research at the University of Washington (UW), Associate Dean for Translational Health Sciences in the UW School of Medicine, Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at UW and a Member of the Fred Hutchinson Cancer Research Center. She is the Director of UW Medicine’s Cancer Vaccine Institute.

Her research interest is in the discovery of new molecular immunologic targets in solid tumors for the development of vaccine and cellular therapy for the treatment and prevention of common malignancies. In addition, her group evaluates the use of the immune system to aid in the diagnosis of cancer and develops novel assays and approaches to quantitate and characterize human immunity. She holds several patents in the field of targeted cancer immunotherapy and immune-based diagnostics.

Dr. Disis is a member of the American Society of Clinical Investigation and the Association of American Physicians. She holds a leadership award from the Komen for the Cure Foundation and is an American Cancer Society Clinical Professor. Dr. Disis is the Editor-in-Chief of JAMA Oncology.


Dr. Gong Chen, Sun Yat-sen University Cancer Center

  • Vice general secretary, Chinese Society of Clinical Oncology
  • Member, Colorectal Track, Committee of Scientific Program, ASCO, 2015-2017
  • Director, Colorectal Branch, Guangdong Anticancer Association
  • Past Director, CSCO(Chinese Society of Clinical Oncology)Young Committee, 2013-2017
  • Member, Beijing CSCO Funding of Clinical Study
  • Member of panel, Expert Committee of GIST, GI NETs, Colorectal Cancer of CSCO
  • Member, Standing Committee, Colorectal Surgeon Branch, Chinese Association of Doctor
  • Member, ESMO/ Member, ASCO
  • Editor, Chinese version of colorectal cancer, Annals of Oncology
  • Editor, Chinese version, The Oncologist
  • Editor, Chinese version, New England Journal of Medicine

Experience in clinical study:

  • Co-investigator for some international multicenter RCTs, including MASCOT, AVANT, LanGIST, GRID, ASCOLT, etc.
  • Main translator for Chinese version of NCCN guidelines of colorectal cancer since 2007


  • About 30 publications as 1st author and corresponding author, including SCI journals, such as Dis colon & rectum, J Cancer Res Clin Oncol, Ann Oncol, Int J Colorectal Dis, BMC Cancer, Cancer, British J Cancer, Plos ONE, Chinese Journal of Cancer, Scientific Report, Cancer Medicine, etc.


Dr. Junli Xue, Shanghai East Hospital

  • Secretary of CSCO anti-cancer drug safety management committee
  • Committee member of CSCO Young committee
  • Standing committee member of CSCO immuno-oncology committee
  • Secretary of National Health Commission Oncology Continuing Education Committee
  • Vice Secretary of China Pharmaceutical Innovation and Research Development Association (PhIRDA) anti-tumor drug clinical research Committee
  • Youth editor of "Journal of Chinese Oncology"
  • Editor of "Journal of Multidisciplinary Cancer Management"


Dr. Xiaotian Zhang, Beijing University Cancer Hospital

  • M.D., Chief Physician, Associate Professor, Master Supervisor;
  • Deputy Director of Department of Gastrointestinal Medical Oncology and International Cooperation and Exchange Department, Peking University Cancer Hospital;
  • Executive Deputy Director of Internal Medicine Teaching and Research Office
  • Chairman of Youth Expert Committee of Chinese Society of Clinical Oncology
  • Member of Executive Committee of Chinese Society of Clinical Oncology
  • Member of Gastric Cancer Committee, Chinese Anti-Cancer Association
  • Secretary General of Tumor Nutrition Therapy and Support Committee of Chinese Anti-Cancer Association, Group Leader of Chemotherapy Nutrition Group
  • Standing member of gastrointestinal sub committee of geriatric oncology Committee of Chinese Geriatric Society
  • Member of Evidence-based Medicine Group of the Sixth Committee of Clinical Epidemiology Branch, Chinese Medical Association
  • Reviewer Experts in Journal of Clinical Oncology, Chinese Journal of Oncology and Chinese Medical Journal, Editorial Board of Chinese Journal of Clinical Nutrition and Chinese Journal of PLA Medicine; Responsible for more than ten phase II and III international multicenter clinical studies and a number of domestic phase II and III clinical studies; Published more than ten SCI articles and dozens of core journals; Participated in the compilation of monograph "Advanced Tutorial in Oncology", etc.







Exclusive Live Streaming Platform:



Welcome to join the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.